Wilmington, Delaware, United States, June 02, 2023 (GLOBE NEWSWIRE) -- The global respiratory virus infection drugs market is projected to flourish at a CAGR of nearly 7% from 2022 to 2030. As per the report published by TMR, the global respiratory virus infection drugs market is expected to exceed a value of US$ 82.8 billion by 2030. The market was valued at over US$ 38.6 billion in 2019.

The market size is expected to continue expanding with the ongoing focus on respiratory health and the need for antiviral therapies. Respiratory viral infections are caused by viruses that primarily affect the respiratory system, including the common cold, influenza, respiratory syncytial virus (RSV), and COVID-19.

Download Sample Copy with Graphs & List of Figures@ www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30551

The increasing prevalence of respiratory viral infection across the globe and increasing demand for higher therapeutics are expected to propel the respiratory viral infections drug market during the forecast period. Increasing focus on personalized medicine and advances in molecular diagnostics and genomic profiling are expected to boost the respiratory virus infection drugs market

Key Takeaways from the Market Report

  • As of 2023, the respiratory virus infection drugs market is forecast to reach US$ 50.9 billion
  • Based on infection type, the respiratory syncytial virus (RSV) infection segment is expected to account for the highest market share in 2031.
  • Based on distribution channel, the hospital pharmacies segment remains the most favored medical setting in the market
  • North America is projected to be the lucrative market for respiratory virus infection drugs market

Respiratory Virus Infection Drugs Market: Prominent Drivers and Trends

  • The increasing healthcare expenditure and growing technological advancement in healthcare settings and increased awareness to drive the market growth during the forecast period
  • The global respiratory virus infection drugs market has witnessed substantial growth due to the increasing prevalence of respiratory viral infections and the demand for effective treatment options.
  • Increasing demand for combination therapy as the number of patients with combination therapy has increased, this offers an opportunity for market expansion.
  • Technological innovation and an increase in research & development activities and advancements in the formulation of high therapeutics treatment products accelerate the growth of the market during the forecast period

Expand Operations in the Future – To Get Requisite Details, Ask For a Custom Report: www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=30551

Respiratory Virus Infection Drugs Market: Regional Analysis

  • North America is expected to lead the respiratory virus infection drugs market due to the presence of major pharmaceutical companies, advanced healthcare infrastructure, and robust research and development activities. The United States is a key market in this region, contributing to a significant share of the market due to the high prevalence of respiratory infections. In recent years, there has been an increased focus on developing antiviral drugs and vaccines for respiratory viruses, particularly during the COVID-19 pandemic.
  • Asia Pacific is expected to witness significant growth in the respiratory virus infection drugs market due to factors such as a large population, increasing awareness about respiratory health, and improving healthcare infrastructure. Countries like China, Japan, India, and South Korea have substantial market potential. In recent years, there has been a rising focus on research and development activities related to respiratory virus infections, particularly with the emergence of novel viruses like SARS-CoV-2.

Competitive Landscape

Transparency Market Research has profiled the following players in its global respiratory virus infection drugs market report:

  • GlaxoSmithKline Plc.
  • Merck & Co., Inc.
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Cipla, Inc.
  • CHIESI Farmaceutici S.p.A.
  • Orion Corporation

The key respiratory virus infection drugs market players are engaged in regulatory approvals, the launch of new products, and new and strategic collaborations. Some specific developments are as follows:

  • AstraZeneca is a global pharmaceutical company that has been actively involved in respiratory research and development. They have worked on the development of antiviral drugs and vaccines for various respiratory viruses, including influenza.
  • GSK is a major pharmaceutical company with a focus on respiratory diseases. They have been involved in the development of vaccines and antiviral drugs for respiratory viruses such as influenza and respiratory syncytial virus (RSV).

Buy this Premium Research Report | Immediate Delivery Available at www.transparencymarketresearch.com/checkout.php?rep_id=30551&ltype=S

Respiratory Virus Infection Drugs Market: Key Segments

Drug Type

  • Antibiotics
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Cough Suppressants
  • Nasal Decongestants
  • Others

Infection Type

  • Respiratory Syncytial Virus (RSV) Infection
  • Influenza Virus Infection
  • Parainfluenza Virus Infection
  • Adenovirus Infection
  • Rhinovirus Infection
  • Others

Route of Administration

Mode of Purchase

  • Prescription-based Drugs
  • Over-the-counter Drugs

Distribution Channel

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Clinics
  • Others

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Contact:
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Websitewww.transparencymarketresearch.com
Blogtmrblog.com
Email: [email protected]

Source link

NEW YORK - Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older.

ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains and was observed to be safe and effective.

'A vaccine to help prevent RSV had been an elusive public health goal for more than half a century. Today's approval is a monumental step forward in delivering on Pfizer's commitment to help alleviate the significant burden of RSV in higher-risk populations, which includes older adults,' said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer. 'ABRYSVO will address a need to help protect older adults against the potentially serious consequences of RSV disease. We are extremely grateful to the clinical trial participants, study investigator teams and our dedicated Pfizer colleagues for their roles in making this vaccine available.'

The FDA's decision is based on the data from the pivotal Phase 3 clinical trial (NCT05035212) RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV disease). RENOIR is a global, randomized, double-blind, placebo-controlled study designed to assess the efficacy, immunogenicity, and safety of a single dose of the vaccinein adults 60 years of age and older. RENOIR has enrolled approximately 37,000 participants, randomized to receive RSVpreF 120 g or placebo in a 1:1 ratio. The results were recently published in The New England Journal of Medicine. RENOIR is ongoing, with efficacy data being collected in the second RSV season in the study.

'This past RSV season demonstrated the serious consequences and potential health risks this virus poses for older adults,' said Edward E. Walsh, MD, Professor of Medicine, University of Rochester Medical Center, and principal RENOIR investigator. 'Today's FDA approval of ABRYSVO recognizes significant scientific progress, and importantly helps provide older adults potential protection against RSV and an opportunity to improve community health by helping prevent the disease.'

RSV is a contagious virus and a common cause of respiratory illness worldwide.2 The virus can affect the lungs and breathing passages of an infected individual, potentially causing severe illness or death.3,4,5 In the U.S., the burden RSV causes in older adults is considerable. The severity of RSV disease can increase with age and comorbidities, such as chronic obstructive pulmonary disease, asthma, and congestive heart failure.6

The U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) will meet on June 21, 2023, to discuss recommendations for the appropriate use of RSV vaccines in older adults. Pending the outcome of this meeting, Pfizer anticipates supply availability in Q3 2023 ahead of the anticipated RSV season this fall.

Earlier this month, Pfizer reported positive top-line results from the Phase 3 study evaluating the safety and immunogenicity of ABRYSVO coadministered with seasonal inactivated influenza vaccine (SIIV) in adults 65 years and older.7 Pfizer intends to publish these results in a peer-reviewed scientific journal. Earlier this month, Pfizer also announced it would be initiating multiple clinical trials evaluating RSVpreF in healthy children ages 2-5; children ages 5-18 with underlying medical conditions; adults ages 18-60 at high-risk due to underlying medical conditions and adults ages 18 and older who are immunocompromised and at high-risk for RSV.8

About ABRYSVO Regulatory Review

On March 24, 2022, Pfizer announced the FDA granted Breakthrough Therapy Designation for ABRYSVO for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older. This decision was followed by the FDA's acceptance of ABRYSVO's Biologics License Application (BLA) under priority review for older adults in November 2022.

Pfizer is currently the only company pursuing regulatory applications for an RSV investigational vaccine candidate for both an indication to help protect older adults, as well as an indication to help protect infants through maternal immunization. Previously, Pfizer announced that the FDA had granted priority review for a BLA for RSVpreF for the prevention of lower respiratory tract and severe lower respiratory tract disease caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals. Earlier this month, Pfizer announced that the FDA's Vaccines and Related Biological Products Advisory Committee voted that available data support the efficacy and safety of RSVpreF for the maternal indication. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date in August 2023.

In February 2023, it was announced that the European Medicines Agency (EMA) accepted for review Pfizer's Marketing Authorization Application (MAA) under accelerated assessment for RSVpreF, as submitted for both older adults and maternal immunization to help protect infants against RSV. The formal review process by the EMA's Committee for Medicinal Products for Human Use (CHMP) currently is ongoing. Also in February 2023, Pfizer Japan announced an application was filed with the Ministry of Health, Labor and Welfare for RSVpreF as a maternal immunization to help protect infants against RSV. In April 2023, Pfizer Canada announced Health Canada accepted RSVpreF for review for both individuals ages 60 and older and as a maternal immunization to help protect infants against RSV.

About Pfizer: Breakthroughs That Change Patients' Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com.

DISCLOSURE NOTICE

The information contained in this release is as of May 31, 2023. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about ABRYSVO (RSVpreF), including its potential benefits, an approval in the U.S. for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older, an application pending in the U.S. for RSVpreF for the prevention of lower respiratory tract and severe lower respiratory tract disease caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals, applications pending for RSVpreF in other jurisdictions and plans to initiate clinical trials in other populations, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of ABRYSVO (RSVpreF); the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data, including the risk that final results from the Phase 3 trials could differ from the interim data;the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when biologic license applications may be filed in particular jurisdictions for ABRYSVO (RSVpreF) for any potential indications; whether and when any applications that may be pending or filed for ABRYSVO (RSVpreF) may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether ABRYSVO (RSVpreF) for any such indications will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of ABRYSVO (RSVpreF); uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities regarding ABRYSVO (RSVpreF) and uncertainties regarding the commercial impact of any such recommendations; uncertainties regarding the impact of COVID-19 on our business, operations and financial results and competitive developments.

Contact:

Email: [email protected]

Tel: +1 (212) 733-1226

Source link

Hospitals reported a "large spike" of children with brain infections this past winter to the highest levels seen in several years, the Centers for Disease Control and Prevention said Thursday, but cases still remain rare overall.

The new findings were published in the CDC's Morbidity and Mortality Weekly Report, updating a previous analysis from the same database run by the Children's Hospital Association.

The CDC first began probing a potential increase in "pediatric intracranial infections" earlier last year, after doctors reported an uptick of these very rare hospitalizations, with many children infected by the bacteria Streptococcus.

Cases had initially fallen steeply after the COVID-19 pandemic began. They climbed again to a peak in March 2022, marking what appeared to be a return to levels "consistent with historical seasonal fluctuations" before the pandemic.

But health authorities in Nevada were among those to raise the alarm over another surge of the very rare brain infections this past winter that appeared to be climbing to levels beyond previous peaks seen before the pandemic.

Investigators suspected the increase could be linked to a resurgence in the wake of Nevada lifting its COVID-19 masking requirements.

The seasonal patterns of respiratory infections like influenza and RSV had also been disrupted during the first years of the COVID-19 pandemic, before returning to larger peaks this past winter.

The CDC's latest analysis finds that the monthly pace of patients diagnosed with these brain infections never returned to its "prepandemic baseline" after climbing last year.

"During January-March 2023, case counts began to decline but remained above the baseline maximum. Although some variability between U.S. Census Bureau regions was observed, overall patterns were generally similar," the report's authors wrote.

Across the 37 pediatric hospitals in the database going back to 2016, a median of 34 cases had been reported each month before the pandemic.

At its previous peak, 61 cases were tallied over the winter of 2016 to 2017. This past winter, cases peaked at 102 in December.

Pediatric intracranial infections investigated by the CDC – which include pus pooling in abscesses or empyemas around the brain – are a very rare but serious complication that has been seen from Streptococcus bacteria.

The vast majority of infections from Streptococcus only result in symptoms like strep throat, alongside other germs that spread largely from the nose and throat.

But in rare cases, invasive diseases can progress from headaches to more worrying signs like seizures and changes in mental status.

"In terms of symptoms, they can initially be very subtle for those presenting, which is sometimes why there is a little bit of a delay in diagnosis," the CDC's Jessica Penney said at an agency meeting in April, discussing early results from their probe.

President Biden falls on stage at Air Force Academy commencement

Destruction from Russia's war on Ukraine revealed in new before and after satellite images

Comer says Wray confirmed existence of record alleging Biden bribery scheme

Source link

Have you been sick in the last few months? I’m talking about a really nasty upper respiratory tract infection. Symptoms include sore throat, stuffy nose, fever and a horrible hacking cough! If that sounds like a typical cold, I am here to tell you that it’s much worse. I speak with some authority because I am pretty sure I caught this virus around mid-March. That’s when human metapneumovirus (aka HMPV) was spreading like crazy.

Human Metapneumovirus (HMPV)

The CNN headline (May 29, 2023) about HMPV caught our attention:

Doctors say this is the most important virus you’ve never heard of

We had never heard of HMPV, but it certainly sounded like what hit our family. We had all traveled to Longmont, Colorado, for a memorial service. Everyone tested for COVID before leaving home and again when we arrived in Colorado. We also tested when we got back home several days later.

One person came from Portland, Oregon and was sniffling and coughing. She was negative for COVID, several times. But within a few days of returning home, almost everyone was sick with a really nasty upper respiratory tract infection. We all tested again, and again we were all negative for COVID-19.

Most of us were coughing up a storm. And the cough persisted for weeks. It took me almost two months to fully get over the lung infection. That makes me think that we caught human metapneumovirus!

HMPV Spiked In Mid March!

Here is a link to the CDC’s human metapneumovirus (hMPV) data for the US. It comes from The National Respiratory and Enteric Virus Surveillance System (NREVSS).

If you look at the graph you will see that cases of HMPV started showing up in January, 2023. They peaked in March and were starting to decline towards the end of April. Those dates certainly corresponded to our upper respiratory tract infections.

What Is HMPV Anyway?

According to the CDC:

“Human metapneumovirus (HMPV) can cause upper and lower respiratory disease in people of all ages, especially among young children, older adults, and people with weakened immune systems. Discovered in 2001, HMPV is in the Pneumoviridae family along with respiratory syncytial virus (RSV).”

What jumps out for me is that this virus was only “discovered” in 2001 by Dutch researchers. That means a lot of healthcare providers probably never learned about it in school. It has almost assuredly been making people sick for many decades, though.

Although the symptoms are similar to the common cold, there is nothing common about HMPV. This virus is within the Paramyxoviridae family. It is a major cause of respiratory infections in humans, but it has flown under the radar for a long time. I’ll bet you never heard of HMPV before either.

The CDC describes symptoms this way:

“Symptoms commonly associated with HMPV include cough, fever, nasal congestion, and shortness of breath. Clinical symptoms of HMPV infection may progress to bronchitis or pneumonia and are similar to other viruses that cause upper and lower respiratory infections. The estimated incubation period is 3 to 6 days, and the median duration of illness can vary depending upon severity but is similar to other respiratory infections caused by viruses.”

That certainly describes our experience. Our family came down with this “bug” within about 3 to 6 days of exposure. And it was a lot worse than the “common cold.” For most people, it acts like a horrible cold, but for the very young and the very old, it can be deadly.

There are no easy tests for HMPV, no vaccinations and no treatments.

The CDC offers the standard recommendations for any viral infection. It tells doctors to advise patients to follow these steps:

  • Wash their hands often with soap and water for at least 20 seconds (see CDC’s Clean Hands Save Lives!).
  • Avoid touching their eyes, nose, or mouth with unwashed hands.
  • Avoid close contact with people who are sick.

That’s pretty much what the CDC told us at the start of the COVID pandemic. How well did that work?

Can You Avoid Catching HMPV?

Let’s be honest, we do not have good strategies to prevent virus-related upper respiratory tract infections. All the experts we have consulted over the last few years point out that viruses like SARS-CoV-2 float through the air. Plexiglass barriers and six feet of distance will not protect you from all of them.

Just imagine someone smoking a cigar in a supermarket or a bank. I know that is hard to visualize these days, but humor me. If you can see smoke or even smell it, chances are pretty good you are breathing in particles that are comparable to viruses.

Dr. Linsey Marr is one of the world’s leading experts on viral transmission and air quality. We have interviewed her a couple of times on our nationally syndicated public radio show. Here is a link to Show 1253: The Lessons of COVID-19 on How to Avoid Airborne Viral Transmission. You can listen to the streaming audio by clicking on the arrow inside the green circle below Dr. Marr’s photo. It is well worth a few minutes of your time.

Final Words:

You hear a lot from the CDC about upper respiratory tract infections such as influenza and respiratory syncytial virus (RSV). By the way, the FDA recently announced (May 3, 2023) that it approved an RSV vaccine (Arexvy). On May 31, 2023 Pfizer announced that it too had received approval to sell an RSV vaccine (Abrysvo). These vaccines have the green light for “individuals 60 years and older.”

You will no doubt be encouraged to get a flu shot this coming fall and, if you are over 60, an RSV vaccination. No one will say much, if anything, about HMPV. And yet it probably causes as much illness as influenza or RSV (Viruses, Jan. 2013).

Did you catch a nasty upper respiratory tract infection in the last few months? If so, please share your experience in the comment section below. If you had a cough, please describe it so that other readers will have some sense of what it was like.

Please share this article with friends and family so that they too will learn about HMSV. It’s easy. Just scroll to the top of the page and click on the icons for email, Twitter or Facebook. You can also encourage your contacts to subscribe to our free newsletter at this link. Thank you for supporting The People’s Pharmacy.

Source link

Last Updated: June 01, 2023, 15:49 IST

Washington D.C., United States of America (USA)

An ambulance is seen outside the Erie County Medical Center Hospital in Buffalo, New York. (Credits: Reuters)

An ambulance is seen outside the Erie County Medical Center Hospital in Buffalo, New York. (Credits: Reuters)

Human Metapneumovirus: Unlike Covid-19 or flu, there is no specific antiviral therapy to treat HMPV and no vaccine to prevent HMPV

In the past winter, the respiratory viruses like RSV and Covid-19 made the headlines, but this summer a virus is on the rise in the US and causing flu and lung infection among the patients.

The US Center for Disease Control and Prevention’s respiratory virus surveillance systems has warned that cases of human metapneumovirus, or HMPV, has spiked this spring, CNN reported.

In March, around 11% of tested specimens were positive for HMPV, raising concerns in US. According to a study, it was the second most common cause of respiratory infections in kids behind Respiratory Syncytial Virus (RSV).

Here is all you need to know about the Human Metapneumovirus or HMPV:

  1. Human metapneumovirus can cause upper and lower respiratory disease in people regardless of age, especially among young children, old people and those with weakened immune systems.
  2. HMPV symptoms include cough, fever, nasal congestion and shortness of breath.
  3. Currently, the virus has filled hospital intensive care units with young children and old people. During its peak in mid-March, around 11% of tested specimens were positive for HMPV, a number that’s about 36% higher than the average, pre-pandemic seasonal peak of 7% test positivity.
  4. The infection may progress among patients to develop bronchitis or pneumonia and the symptoms are similar to other viruses that cause upper and lower respiratory infections.
  5. The estimated incubation period is 3 to 6 days, and the median duration of illness can vary depending upon severity but is similar to other respiratory infections caused by viruses, the CDC said.
  6. HMPV is most likely to spread from an infected person to others through coughing, sneezing, close personal contact like touching or shaking hands and touching objects or surfaces that have the viruses on them.
  7. The circulation of the virus begins in winter and lasts until or through spring. Dr John Williams, a pediatrician at the University of Pittsburgh, called it, “the most important virus you’ve never heard of.” Human metapneumovirus is infecting a significant proportion of patients, as many cases as RSV or influenza.
  8. Unlike Covid-19 or flu, there is no specific antiviral therapy to treat HMPV and no vaccine to prevent HMPV. Instead, the doctors can treat seriously ill patients by treating to their symptoms.
  9. The precautions against the virus are similar to other viral diseases like washing hands, avoiding touching eyes, nose or mouth with unwashed hand and avoiding close contact with people who are sick.
  10. A study conducted in New York over four winters discovered that HMPV was as common among older patients in hospitals as RSV and the flu. It was also responsible for fatal cases of pneumonia in older people.

Source link

(SACRAMENTO)

If you came down with a respiratory infection in the spring and it wasn’t influenza (flu), COVID-19 or RSV, it may have been a virus you’ve never heard of.

That’s because cases of human metapneumovirus, or HMPV, surged across the U.S. in March.

According to the Centers for Disease Control and Prevention (CDC), 19.6% of antigen tests and 10.9% of PCR tests for HMPV were positive in early and mid-March. The numbers are about 36% higher than before the pandemic.

The virus is seasonal, like the annual flu. In the United States, HMPV infections begin circulating in winter and last through spring. And the good news is that levels have dropped.

“HMPV is not something most people need to worry about. It’s essentially another cause of the common cold,” said Larissa May, a professor of emergency medicine and an expert in public health and testing for infectious diseases. 

Why you likely won’t know if you had HMPV

There are no antiviral drugs specifically for HMPV like there are for the flu and COVID-19. Which is why physicians usually don’t test for it.

“The treatment of mild or moderate viral upper respiratory infections is supportive no matter what the viral cause, so we generally do not recommend testing for most outpatients,” said Dean Blumberg, chief of pediatric infectious diseases.

Treatment is the same as a cold — lots of fluids to prevent dehydration, decongestants to reduce congestion, and pain relievers like ibuprofen and other NSAIDs for body aches.

May noted that it’s a common misunderstanding that antibiotics can help. “They will not help you recover from HMPV because antibiotics do not work against viruses,” May said. 

The virus was first discovered in 2001. HMPV is in the Pneumoviridae family, along with the more commonly known respiratory syncytial virus or RSV. 

Dean Blumberg

Although in most people, HMPV causes a mild cold, it may cause more severe disease resulting in hospitalization for some.”Dean Blumberg, chief of pediatric infectious diseases

“HMPV causes disease very similar to RSV,” Blumberg said. “This includes upper respiratory symptoms that sometimes progress to pneumonia or bronchiolitis and wheezing. Although in most people, HMPV causes a mild cold, it may cause more severe disease resulting in hospitalization for some.”

The virus can cause upper and lower respiratory disease in people of all ages but is most common in children, especially those under 5 years of age.

According to Blumberg, infants and young children less than 2 years of age are most at risk for complications like bronchiolitis. “Children born prematurely, with heart or lung disease, or weakened immune systems are at higher risk for severe disease,” Blumberg said.

Others at higher risk are people who have had organ transplants, those with cancer, those who take long-term steroids and those over 75 years of age.

UC Davis test detects over 20 respiratory viruses

Currently, there are no home tests for HMPV. For hospitalized or high-risk patients with respiratory illness, UC Davis has a combined test that can help diagnose multiple viruses and bacteria that commonly cause respiratory disease.

Similar to a PCR COVID-19 test, the multiplex respiratory panel uses a nasal swab specimen. It can detect non-COVID coronavirus, parainfluenza, Flu A and B, RSV, C. pneumoniae, M. pneumoniae, rhinovirus, enterovirus, and adenovirus. It can also differentiate sub-types of these pathogens.

“The panel lets us look at all the common causes of respiratory disease all in one test. In practice, it is used when common pathogens like flu A and B, SARS-CoV-2 and RSV are not detected with other routine PCR platforms, and there's a critical need to know what else could be causing the respiratory infection,” said Nam Tran, a professor and senior director of clinical pathology at UC Davis Health.

May noted, “Testing isn’t generally needed for people who don’t have complications. They are only needed for certain patients, like those who are immunosuppressed or admitted to the hospital with a respiratory infection.”

Because testing is primarily conducted in a hospital setting, the actual number of HPMV infections every year is unknown. A 2020 study published in The Lancet found that there were an estimated 14.2 million cases of HPMV globally in children younger than 5 years old.

A graph showing a blue line and a red line peaking during the month of March.
Positivity rates for human metapneumovirus (HMPV) spiked in the U.S. this spring according to the CDC.

Symptoms and how to protect yourself

Symptoms of HMPV are similar to a cold and include a sore throat, chest congestion and a cough, nasal congestion and sometimes a fever.

“HMPV may be prevented by respiratory hygiene, such as avoiding and covering coughs and good hand hygiene — washing hands after contact with potentially infectious secretions or surfaces,” Blumberg said.

If you have cold-like symptoms, to prevent spreading the virus you should:

  • cover your mouth and nose when coughing and sneezing
  • wash your hands frequently with soap and water for at least 20 seconds
  • avoid sharing cups and eating utensils
  • refrain from kissing others
  • stay at home when sick

When to see a doctor

You should call your doctor if you or your child has one or more of these conditions:

  • difficulty breathing
  • chest pain
  • difficulty keeping fluids down
  • symptoms that last more than 10 days
  • symptoms that are severe or unusual
  • if your child is younger than 3 months of age and has a fever or is lethargic

You should also call your doctor right away if you are at high risk for serious complications and get symptoms such as fever, chills, and muscle or body aches.

Resources

Source link

Since mid-2021, global concerns appear to be focusing on scourges other than the Covid-19 pandemic. This disease could nonetheless go through seasonal resurgences as do other respiratory infections, especially the flu. Covid-19 is transmitted mainly through contact with soiled, previously contaminated objects (also referred to as “fomites”) and through the transport and dispersion of particles emitted by infected people. In this regard, it has been established that virions, the extracellular form of viruses, are present and pathogenic in liquid particles produced by infected people when they sneeze or cough, but also when they speak or simply breathe. Virions are found in the sputum of symptomatic people, but also in that of asymptomatic people, who can unknowingly transmit the infection to others who, in turn, will be unaware that they have been contaminated. Airborne transmission of infectious agents carried in liquid particles of different sizes is discussed later in the introduction. It raises concerns, especially since it is not specific to Covid-19; indeed, it is common in many other respiratory diseases such as the other severe acute respiratory syndromes (SARS), Middle East respiratory syndrome (MERS) or the many types of influenza (H1N1) and their variants.

The sizes of particles expectorated depend on the dissemination event, and even on the human behind it (in other words, two people do not produce the same spectrum of liquid particles when breathing or coughing). The range of sizes extends over several orders of magnitude (from 0.1 to 1000 µm in aerodynamic diameter). A cut-off diameter (around 5 to 10 µm) separates the finer particles, which are “real” aerosols sustainably suspended in the air, from the larger particles, which, according to the conditions of their emission, either settle almost immediately on accessible surfaces or behave like projectiles. In this article, we consider particles of discrete sizes and use the word “droplets” for particles whose diameter is either 1 or 10 µm, whereas the word “drops” refers to particles with a diameter of either 100 or 1000 µm. Also, the word “diameter” implicitly means “aerodynamic diameter.”

On a global level, not all countries agree on the measures to be taken in the face of Covid-19: some apply strict testing and lock-down measures, while others put up with the presence of the disease as long as it remains limited. However, the World Health Organization (WHO) like the health institutions of many countries ended up advocating the mask use as valuable for limiting the dissemination of virions exhaled by infected people during respiratory events. Mask use was systematically made compulsory during the acute phases of the pandemic. It has persisted in places such as hospitals, pharmacies and public transport. Even though mask use currently remains compulsory only in certain countries, it will clearly become advisable again in the event of a Covid-19 resurgence, wherever it may occur.

In a previous article1, we attempted to fully demonstrate the value of Computational Fluid Dynamics (CFD) to account for the three-dimensional space and time dispersion of particles emitted by people infected with diseases leading to expectoration of pathogens such as virions. To illustrate our point, we studied the risk of Covid-19 transmission among public transport passengers. We created a twin experiment by reproducing the numerical mock-up of a commuter train car in which human manikins were placed. We assumed that an infected individual emitted droplets and drops while breathing and during coughing episodes. The particles were transported by the ventilation system of the coach and exhibited totally different aerodynamic behaviour depending on whether they were droplets (which perfectly followed the streamlines) or drops (which separated from the carrier fluid by their inertia and tended to sediment in the immediate vicinity of the spreader). In addition, the cough was characterised by the initial momentum given to the emitted particles. While the droplets adapted very quickly to the flow around them, this was not the case for the largest drops, which adopted a ballistic behaviour. This phenomenology was highlighted in our three-dimensional simulations, which examined the turbulent flow within the coach and the dispersion of particles of different sizes (using an Eulerian approach and a Lagrangian approach that led to similar results).

While our article1 enabled us to present and validate our CFD model, it was limited to the case in which passengers did not wear masks. This situation corresponds to what prevails today in places where the Covid-19 outbreak seems to be behind us, at least in some countries. When the epidemic was active, however, many governments mandated the wearing of masks on public transport; this remains the case in some parts of the world and could become widespread again in the event of a resurgence of Covid-19 or other respiratory diseases. In addition, we thought it would be interesting and useful to attempt to carry out CFD simulations featuring mask use by passengers. We were particularly interested in knowing if mask use could effectively reduce the dissemination of virions in a public space such as a railway coach. This led us to undertake simulations involving, once again, a twin experiment in a railway coach, this time with passengers wearing masks and, among them, one passenger assumed to be infected with the Covid-19 disease. In the simulations reported in this article as in the previous one, the liquid particles are assumed not to evaporate and we study their spatial and temporal distribution around the human manikins occupying the railway coach.

This new research article is structured as follows. We first present a review of the literature: on one hand, we take stock of what is known or still debated at the end of 2022 regarding the transmission of the SARS-CoV-2 virus; on the other hand, we examine the influence of mask use on the droplets and drops produced by an individual breathing and coughing. As there are many types of masks, special emphasis is placed on the surgical mask, which is very widespread due to its particularly low cost. We then devote a part of the article to the results of our modelling and simulation work. First we consider the head and bust portion of a human manikin, which is immersed in a motionless atmosphere; this allows us to examine the situations in which the manikin wears a tight-fitting mask, a loose-fitting mask, or no mask at all. We next present results obtained with complete human manikins wearing masks and placed in a commuter train, with one of the passengers being infected with the Covid-19 disease. In the next section of the article, we present a general discussion about the results obtained and the perspectives offered by our numerical approach in terms of scientific developments and operational applications. Part of the article is devoted to the methods used in the numerical study. In particular, we explain our choices regarding the production of droplets and drops, depending on whether the manikins wear more or less well-fitting masks, and regarding the aerodynamic conditions in the railway coach. We also present the CFD tool implemented in the study, as well as the computational resources and the associated computation times.

Aerial transmission of the SARS-CoV-2 virus and other pathogenic respiratory agents

The mode of transmission of the SARS-CoV-2 virus (which causes Covid-19) was intensely debated in 2020, as the results were to determine the healthcare responses needing to be made. In July 2020, the WHO2 recognised that the SARS-CoV-2 virus could be transmitted from person to person through the air. This virus is known to be carried in liquid particles exhaled through the mouth and the nose, particularly when coughing, sneezing, speaking, singing or breathing3. These particles, whose exact chemical composition remains unclear, contain multiple virions of about 100 nm in size4. The combination of entrainment by the airflow, particle inertia, gravity and evaporation determines the evolution of the exhaled particles.

Historically, particles carrying virions have been separated into two categories according to their aerodynamic behaviour5, on the grounds that this dichotomy should be a source of guidance for national health authorities and the WHO. We therefore make a distinction between drops – “visible” particles with a diameter greater than about 5 to 10 µm, which fall under the effect of gravity without having time to evaporate, finally settling on exposed surfaces (fomites) – and droplets, presenting a diameter of less than 5 to 10 µm, which evaporate more or less rapidly to a dry nucleus and remain suspended in the air in the form of an aerosol6. The droplets are carried by the airflow, which depends on the local ventilation conditions7. They are likely both to cause contamination at longer distances and to penetrate deeper into the respiratory tract in comparison to drops8,9. The threshold of 5 to 10 µm that is usually considered has been discussed and questioned during the pandemic3, and it is clear today that all classes of particles must be taken into account, as well as the two modes of transmission at short and long distances10.

The number and size of particles exhaled by a spreader are highly variable. The overall exhalations of a human being are known to contain particles between 0.1 and 1000 µm in aerodynamic diameter, i.e. five orders of magnitude11. Symptomatic and asymptomatic carriers do not a priori produce the same number or the same size of viral particles. In addition, symptomatic carriers do not necessarily excrete higher viral-load drops and droplets than do asymptomatic infected people12. There are also people called “super-spreaders.” It has been shown, for example, that some individuals produce seventeen times more droplets during a cough compared to other individuals13. It has also been shown that the viral load of the particles changes according to the stage of the disease.

The proportion between exhaled drops and droplets is variable and still subject to debate, as is the potential for aerosol contamination. For example, trials7 have shown that 20,000 particles between 0.8 and 5.5 µm, along with 100,000 virions, are emitted every minute during speech. In a series of analyses, aerosols smaller than 5 µm have been shown to contain more SARS-CoV-2 virions than do particles larger than 5 µm14, while other findings tend to go the other way13. The number of exhaled particles varies depending on whether we consider a low-frequency event or a cyclic event. For example, a sneeze can produce around 10,000 particles15, a cough around 10 to 100 times fewer16 and breathing or speaking a minimum of 50 particles per second, but since breathing and speaking are recurrent phenomena, they are probably ten times more important in contamination than coughing or sneezing17.

Experimental work13 makes it possible to assess both the number of particles produced during coughing and speaking and the corresponding viral load. For instance, this work mentions that during a cough, 98% of the volume of particles is made up of drops of 100 to 1000 µm, with more than 20 106 droplets (with a diameter of less than 10 µm) being produced in a single cough. By comparison, the experiment proposed for speech (“stay healthy” pronounced 10 times) produces more than 7 106 droplets. The authors use a viral load estimate of 7 106 virion copies per millilitre of respiratory sample. Measurement of the volume of the cough droplets shows that it has about 104 copies, i.e. one in 2000 droplets contains at least one virion.

Finally, it should be noted that the diameter of the particles varies in the air under the effect of evaporation. The final particle diameter depends on many factors such as initial size, relative humidity, temperature, ventilation flows and residence time11. For example, an average particle size of 2 to 3 µm can be obtained for an initial size of 10 µm18.

While numerous scientific works carried out during the Covid-19 pandemic have supplemented the knowledge acquired over a long period of time on the transmission of infectious agents, many questions about the SARS-CoV-2 virus are not yet clearly resolved, such as the relative contagiousness of drops and droplets according to their diameters, the “minimum dose” to risk contamination, the number of virions exhaled by infected people or the evolution of the pathogenicity of the virions embedded in evaporating drops and droplets.

Use of surgical masks and their effect on aerial transmission

The surgical mask is a single-use respiratory mask whose purpose is to limit to the immediate environment the spread of bacteria and viruses exhaled from the respiratory tract (mouth and nose) of the wearer. Its main purpose is to filter the largest respiratory drops (above a few tens of micrometers). Originally, this type of mask was worn by healthcare professionals during surgery to protect the sterile operating field and the patient receiving care. It is also worn by patients with a disease whose contagious agent is airborne.

When used correctly, a surgical mask quite successfully contains the dispersion of respiratory drops produced during a sneeze or a cough. It is commonly accepted to be an effective device for blocking drops projected by the wearer and measuring several tens of microns. It has been shown to greatly limit the transmission of airborne viruses (influenza, coronavirus, etc.) by infected people19. That said, it is not very effective in stopping the transmission of fine aerosols smaller than 5 µm20, and its effectiveness depends on its design, the materials used in its manufacture, its dimensions and its fit on the face.

Above all, the surgical mask protects the individuals surrounding the person wearing it – but the wearer is also protected from projections of drops, though it is unknown to what extent exactly. The protection provided by a surgical mask during inhalation is real, but unquantified and extremely variable. Such a mask is not designed to protect the wearer from inhaling airborne bacteria or viral particles.

Generally speaking, filtering facepiece (FFP) masks are personal respiratory equipment defined by standards such as EN 14921 in the European Union. This type of mask protects the wearer of the mask against the inhalation of particles in suspension in the air (average aerosol diameter of 0.6 μm) and drops of larger diameters. Leaks inside the mask are also standardised. There are several types of masks – FFP1, FFP2 and FFP3 – categorized by their filtration of aerosols with an average diameter of 0.6 µm (respectively 80%, 94% and 99%) and their degree of leakage towards the inside of the masks (respectively less than 22%, 8% and 2%).

The surgical mask is not a filtering respiratory device and cannot be certified as such. To be approved, however, it must meet standardised criteria based on bacterial filtration efficiency (BFE; during exhalation only) and splash resistance. For instance, in the EU, types I and II correspond to masks with, respectively, BEF > 95% and BEF > 98% of an expired aerosol with an average diameter of 3 µm, while type III is like type II but is also resistant to splash. There exists a test protocol for evaluating BFE22 whose presentation would be beyond the scope of this article, as would be the description of all standards that apply to masks intended for workers (for instance, medical staff) or the general public. The reader is referred, for example, to an Internet site23 that provides an interesting compilation of the standards that apply in the USA, the EU, China, Japan, South Korea and elsewhere.

Particle filtration efficiency during exhalation

Several authors have studied the filtration efficiency of surgical masks for various particle sizes, including fine particles. In one experiment24, different types of masks were tested with the assumption that they were perfectly fitted, i.e. without leakage between the mask and the wearer’s face. Drops with a diameter greater than 10 µm were generally filtered by the different masks, as were particles with a diameter less than 200 nm, due to the Brownian effect. Still, none of the masks tested, apart from FFP2 N95, could filter 100% of the droplets of intermediate size whose diameter was between 1 and 5 μm. In this experiment, even with a perfectly tight fit, aerosol leakage through the surgical mask represented 0.1% to 0.2% of the exhaled particles. Another experimental work25 involving different types of perfectly fitting surgical masks gave even poorer overall aerosol filtration efficiency results for surgical masks, with about 50% of particles with a diameter between 1 and 8 µm being retained.

In practice, leakage can be very significant at the wearer’s face, because the mask lets a large quantity of air pass around its perimeter. For instance, the presence of fog on eyeglasses shows that a good deal of air is exiting directly without passing through the filter screen. The problem of leaky surgical masks is not new, and it has often been studied already, at least qualitatively, leading to wear and adjustment recommendations for healthcare personnel26. A few precautions can limit the rate of leakage: these include a knot in the ear loops, a well-adjusted nose clip or the use of a cloth mask over the surgical mask, as per CDC recommendations27.

More recently, the problem of leakage from surgical masks has been presented experimentally in a relatively large number of scientific publications. For instance, an experimental reconstitution28 of the cough of a human manikin showed that only 56% of aerosols between 0.1 and 7 µm were filtered by a surgical mask, due to leaks around the edge of the mask. The filtration percentage increased to 77% with adjustment by side knots and the use of a nose clip, and even to 85% when the surgical mask was covered with a cotton mask.

Detailed CFD simulation work carried out on the subject in 2021 by the Riken Scientific Research Institute (Japan)29 also showed that the fraction of aerosols passing through different types of fabric masks without being filtered was larger than 70% with a variable fraction of aerosols leaking through the spaces between the wearer’s face and the mask.

Apart from its more or less effective filtration properties, a surgical mask can significantly reduce the airflow velocity during a sneeze, during a cough or within the respiratory cycle30,31,32,33,34. That said, the inhalation and exhalation phases also increase leaks on the perimeter of the mask due to “pumping” effects. Thus, the air jets resulting from these leaks can be highly turbulent and directional, which increases the effects of aerosol dispersion in the transverse directions but redirects the aerosols in directions that are a priori less problematic than a breath of air emitted directly from the mouth or nose of the wearer35,36.

It is also possible to visualise changes in exhaled airflows through density differences (due to temperature differences between the lukewarm exhalation and the ambient air) by means of the Schlieren process37. In the work cited, the authors showed that the direction and range of the exhaled airflow were modified according to the type of mask worn. Instead of passing through the filtering part of the mask, the air flows partially around the filtering part through leaks. Leakage can be two thirds of the total airflow through all parts of the mask. This fraction is much larger for surgical masks than, for example, FFP masks. The leaks between the mask and the face may be so significant that, according to the authors, the effectiveness of the masks should be considered based on the existence of secondary airflows around the perimeter of the mask, which depends on whether or not the mask is properly worn rather than on its intrinsic filtration efficiency or its ability to reduce the main airflow through the mask.

Looking beyond experimental evaluations, CFD presents the advantage of allowing precise access to airflow velocities and particle trajectories. That said, few simulations involving surgical masks and their inherent leaks have been carried out. One example is given by a CFD study38 of a human manikin wearing a surgical mask, in which the air and droplet leakage through and around the mask were evaluated for a five-second cyclical cough (with 1,008 droplets per cycle and a maximum expectoration velocity of 5 m.s−1). The numerical simulations were carried out with the Open FOAM software using an unsteady RANS approach for turbulence and a Lagrangian approach for particle tracking. The particle diameters were between 1 and 300 µm, and the filtration efficiency of the modelled surgical mask was assumed to be 91%. The authors used these simulations to identify the main locations of the leaks, evaluating the airflow velocities through these leaks to be approximately 0.2–0.4 m.s−1. The results also made it possible to estimate the relative proportions of droplets that were blocked by the mask, that passed through the mask and that escaped through leaks. The positive role of the mask, both in terms of filtration and reduced exhaled flow, was highlighted. Unfortunately, the authors did not establish a connection between the nature of the leakage and the particle diameter.

Particle filtration efficiency during inhalation

There exist no standardised data on wearer protection against incoming aerosols (that can also penetrate inside the mask by passing through the spaces between the wearer’s face and the mask). There have, however, been experimental studies published on this subject39,40,41. Between 20 and 80% of aerosols with a diameter of less than 1 µm passed through the mask, depending on its design, the number of layers, the material used for filtration and the airflow imposed through the mask. In another experimental work42, 20% to 80% of 1– to 3–µm diameter droplets passed through the mask.

On the same topic, an interesting experimental comparison43 was made for different types of masks regarding their filtration efficiency during inhalation (inward) and exhalation (outward). The aerosol diameters were between 0.04 and 1 µm in the first case, and between 2 and 5 µm in the second. The filtration efficiency of the mask was evaluated by tests on a specific test bench using a sample of the mask material (which therefore presents no leaks). In addition, the inward and outward protection efficiencies were determined using tests on manikins (accounting for leaks). For diameters less than 5 µm, the results depend on the diameters, with the exhalation and inhalation filtration efficiencies found to be between 25 and 75%. There is a significant deficiency in the effectiveness of the surgical mask for diameters below 2 µm, whether the wearer is inhaling or exhaling. Above 5 µm, the exhalation and inhalation efficiencies of the surgical mask were comparable (around 75%).

Very few CFD simulations have focused on the filtration of inhaled aerosols through a surgical mask. The study44 considers the head of a human manikin inhaling aerosols through a perfectly fitted surgical mask (with no leaks). The aerosols were between 1 and 20 µm in diameter. The filtration efficiency of the mask was set to 65% for all diameters. The originality of this study resides in its consideration of both the upper airways (nose and pharynx) and the lower airways (mouth and larynx), with the results showing that mask use clearly alters the flow near the nose and mouth. The air velocities were significantly lower and the particles entered less deeply into the respiratory tract favouring the deposition of aerosols in the upper airways (nose). Overall, wearing the mask reduced the quantity inhaled by three and five, respectively, for the 3–10 µm and 15 µm aerosols. For the aerosols of 1–3 µm in diameter, the quantity inhaled was almost the same regardless of whether a mask was worn or not.

Another publication35 presents a CFD and experimental study featuring the head of a human manikin equipped with an FFP2 mask. Even though the mask studied was not a surgical mask, this study enabled the assessment of leak sites around the perimeter of the mask and the way in which these leaks were distributed. The results indicated that, on average, leaks occurred mainly at the level of the nose (35 to 50%), to a lesser extent near the cheeks (20 to 25%) and least of all near the chin (6 to 12%).

Summary of the literature review focusing on surgical masks

A number of studies have examined the effectiveness of surgical masks, though most of them have not been carried out in the context of the Covid-19 pandemic, but instead for other infections (especially influenza). In addition, most of these studies have been experimental and solely qualitative, with different areas of focus (samples of filtering materials, masks placed on human manikins or patient cohorts). Due to differences among the protocols and the challenges involved in making the various measurements, the conclusions of these studies can be contradictory. Nevertheless, the following information can be derived about surgical masks:

  • Filtration efficiency in experiments implying real people or human manikins is lower than that measured using devices for testing masks.

  • A surgical mask contains the dispersion of respiratory drops of more than 10 µm in diameter according to standards. That said, it is much less effective in stopping the transmission of aerosols of less than 3 µm in diameter.

  • For a perfectly fitted surgical mask, the overall filtration efficiency during exhalation is around 50% for 1–8 µm droplets25 or between 50 and 75% for droplets smaller than 2 µm43. Still, for 1–5 µm droplets, leakage is limited to 0.1 to 0.2%24.

  • A surgical mask primarily protects those around the person wearing it. The wearer is also protected from projections of drops without it being known in which proportions exactly. The protection provided to the wearer during inhalation is not standardised. Experimental studies show that 20–100% of 1–3 µm particles pass through the mask39,40,41,42,44.

  • In practice, leakage is significant, and the mask allows large quantities of air and large numbers of particles to pass around it. While these leaks are not precisely quantified, their location is relatively well known. We can retain the following results:

  • During a cough, 56% of 0.1–7 µm droplets are blocked, while the others escape via side leaks28;

  • During a cough, the fractions of droplets blocked by the mask, passing through it and escaping through the leaks have been evaluated, and the velocity through the leaks is 0.2–0.4 m.s−138;

  • In respiratory events, leaks around the edge of the mask are distributed on average as follows: 35 to 50% around the nose, 20 to 25% on each side of the cheeks, and 6 to 12% along the chin35;

  • In respiratory events, the outward and inward filtration efficiencies of a surgical mask are between 25 and 75% for droplets of less than 5 µm in diameter, and they are of the same order for particles larger than 5 µm43.

  • Apart from its filtration properties, a surgical mask can greatly reduce the velocity of the breath of air emitted during the respiratory cycle30,31,32.

Source link

a vet using a stethoscope on a dog in a clinic

Dogs who contract severe cases of respiratory disease may require extensive treatment, as these cases can impact dogs’ long-term health.


Getty Images

 

Dog owners are likely familiar with the respiratory disease commonly known as kennel cough; while most cases have been historically mild, a more severe form of the infection is on the rise.

Because kennel cough is an infectious respiratory disease complex that easily spreads among dogs, Dr. Kathleen Aicher, an assistant professor at the Texas A&M School of Veterinary Medicine and Biomedical Sciences, said it’s important to know the signs and symptoms of the disease as well as what to do if you suspect your dog has been exposed.

“There are a variety of agents that can cause kennel cough, whether bacterial or viral,” Aicher said. “But, sometimes, kennel cough cases can be worsened by other contagious respiratory infections that dogs can get that they are not protected against, or they can become more severely affected, leading to severe kennel cough cases.”

Mild vs. Severe Cases

Traditionally, dogs with a mild case of kennel cough can recover quickly after being prescribed cough suppressants or supportive care that focuses on relieving symptoms, which can include fever, coughing, nasal snuffling or discharge, discharge from the eyes, and sneezing.

On the other hand, dogs who contract severe cases of respiratory disease may require extensive treatment, as these cases can impact dogs’ long-term health. Aicher pointed out that in recent years, veterinarians have observed outbreaks in regions of the country in which younger dogs have been more severely affected.

These dogs have required more diagnostics and supportive care than has historically been the case for “garden variety” kennel cough. Some dogs have developed long-lasting symptoms, which can affect their health for the remainder of their lives.

“Dogs who have a more severe form become affected very quickly and may require hospitalization and oxygen, which are things that dogs with kennel cough don’t usually need,” Aicher said. “Some may have lasting disease or damage in their lungs that persists, leading to the need for longer-term medical therapy or, in rare cases, surgery to remove a diseased portion of the lungs. So it’s important that if owners suspect their dog might have kennel cough that they consult with their veterinarian, regardless of the severity of their symptoms, so that they can know what action to take.”

Prevention

To best protect against contagious respiratory disease, Aicher said owners should ensure that their dogs are vaccinated against bacteria and viruses that can cause kennel cough, such as the bacteria Bordetella and canine influenza.

“In addition to vaccinating dogs, owners should make sure to bring dogs to places that only accept healthy, vaccinated dogs, and if they know their dog is sick or if their dog is exhibiting symptoms of respiratory illness, owners should not bring them around other dogs,” Aicher said. “This will prevent dogs from unknowingly spreading the illness to other dogs, in case they are contagious.”

When To Go To The Vet

If your dog has been around other dogs, such as at a boarding facility or doggy daycare, owners should take heed of any initial symptoms of respiratory diseases your dog may exhibit following their exposure to other dogs.

“If dogs develop a cough, have trouble breathing, or feel poorly after being around other dogs, then their owners should have them seen by a veterinarian as soon as possible or visit an emergency clinic if their veterinarian is not available,” Aicher said.

Before arriving at the clinic or hospital, Aicher strongly recommends that owners inform the veterinary team who will be providing their dog’s care that the incoming patient has been around other dogs, since kennel cough is contagious.

“The veterinary team may choose to wear personal protective equipment (PPE) or bring your dog through a different entrance into the hospital to prevent the disease from spreading easily. They may take additional precautions that would be different if it was for another cause of respiratory symptoms, like heart disease or asthma,” Aicher said.

While contagious respiratory diseases can have devastating effects, Aicher reiterates to owners that their dogs are very likely to recover fully, especially with the guidance of their veterinarian.

“The majority of dogs recover from this disease without any sort of problems, and they go back to living healthy normal lives,” Aicher said. “For those who are more severely affected, talking to a veterinarian sooner and getting their dog checked out are ways that can help with a faster recovery.”

Respiratory diseases can be troubling for dog owners and their furry friends alike. By prioritizing your dog’s respiratory health and remaining vigilant when your dog begins feeling unwell, owners can relax knowing that their pet is protected while also protecting other dogs.

Source link

If you came down with a respiratory infection in the spring and it wasn’t influenza (flu), COVID-19 or RSV, it may have been a virus you’ve never heard of.

That’s because cases of human metapneumovirus, or HMPV, surged across the U.S. in March.

According to the Centers for Disease Control and Prevention (CDC), 19.6% of antigen tests and 10.9% of PCR tests for HMPV were positive in early and mid-March. The numbers are about 36% higher than before the pandemic.

The virus is seasonal, like the annual flu. In the United States, HMPV infections begin circulating in winter and last through spring. And the good news is that levels have dropped.

“HMPV is not something most people need to worry about. It’s essentially another cause of the common cold,” said Larissa May, a professor of emergency medicine and an expert in public health and testing for infectious diseases.

Why you likely won’t know if you had HMPV

There are no antiviral drugs specifically for HMPV like there are for the flu and COVID-19. Which is why physicians usually don’t test for it.

“The treatment of mild or moderate viral upper respiratory infections is supportive no matter what the viral cause, so we generally do not recommend testing for most outpatients,” said Dean Blumberg, chief of pediatric infectious diseases.

Treatment is the same as a cold — lots of fluids to prevent dehydration, decongestants to reduce congestion, and pain relievers like ibuprofen and other NSAIDs for body aches.

May noted that it’s a common misunderstanding that antibiotics can help. “They will not help you recover from HMPV because antibiotics do not work against viruses,” May said.

The virus was first discovered in 2001. HMPV is in the Pneumoviridae family, along with the more commonly known respiratory syncytial virus or RSV.

Dean Blumberg

Although in most people, HMPV causes a mild cold, it may cause more severe disease resulting in hospitalization for some.”-Dean Blumberg, chief of pediatric infectious diseases

“HMPV causes disease very similar to RSV,” Blumberg said. “This includes upper respiratory symptoms that sometimes progress to pneumonia or bronchiolitis and wheezing. Although in most people, HMPV causes a mild cold, it may cause more severe disease resulting in hospitalization for some.”

The virus can cause upper and lower respiratory disease in people of all ages but is most common in children, especially those under 5 years of age.

According to Blumberg, infants and young children less than 2 years of age are most at risk for complications like bronchiolitis. “Children born prematurely, with heart or lung disease, or weakened immune systems are at higher risk for severe disease,” Blumberg said.

Others at higher risk are people who have had organ transplants, those with cancer, those who take long-term steroids and those over 75 years of age.

UC Davis test detects over 20 respiratory viruses

Currently, there are no home tests for HMPV. For hospitalized or high-risk patients with respiratory illness, UC Davis has a combined test that can help diagnose multiple viruses and bacteria that commonly cause respiratory disease.

Similar to a PCR COVID-19 test, the multiplex respiratory panel uses a nasal swab specimen. It can detect non-COVID coronavirus, parainfluenza, Flu A and B, RSV, C. pneumoniae, M. pneumoniae, rhinovirus, enterovirus, and adenovirus. It can also differentiate sub-types of these pathogens.

“The panel lets us look at all the common causes of respiratory disease all in one test. In practice, it is used when common pathogens like flu A and B, SARS-CoV-2 and RSV are not detected with other routine PCR platforms, and there’s a critical need to know what else could be causing the respiratory infection,” said Nam Tran, a professor and senior director of clinical pathology at UC Davis Health.

May noted, “Testing isn’t generally needed for people who don’t have complications. They are only needed for certain patients, like those who are immunosuppressed or admitted to the hospital with a respiratory infection.”

Because testing is primarily conducted in a hospital setting, the actual number of HPMV infections every year is unknown. A 2020 study published in The Lancet found that there were an estimated 14.2 million cases of HPMV globally in children younger than 5 years old.

A graph showing a blue line and a red line peaking during the month of March.
Positivity rates for human metapneumovirus (HMPV) spiked in the U.S. this spring according to the CDC.

Symptoms and how to protect yourself

Symptoms of HMPV are similar to a cold and include a sore throat, chest congestion and a cough, nasal congestion and sometimes a fever.

“HMPV may be prevented by respiratory hygiene, such as avoiding and covering coughs and good hand hygiene — washing hands after contact with potentially infectious secretions or surfaces,” Blumberg said.

If you have cold-like symptoms, to prevent spreading the virus you should:

  • cover your mouth and nose when coughing and sneezing
  • wash your hands frequently with soap and water for at least 20 seconds
  • avoid sharing cups and eating utensils
  • refrain from kissing others
  • stay at home when sick

When to see a doctor

You should call your doctor if you or your child has one or more of these conditions:

  • difficulty breathing
  • chest pain
  • difficulty keeping fluids down
  • symptoms that last more than 10 days
  • symptoms that are severe or unusual
  • if your child is younger than 3 months of age and has a fever or is lethargic

You should also call your doctor right away if you are at high risk for serious complications and get symptoms such as fever, chills, and muscle or body aches.

Resources

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.

Source link

Last night, Pfizer Inc. announced the US Food and Drug Administration (FDA) approved their respiratory syncytial virus (RSV) vaccine, Abrysvo, for older adults. This approval allows the use of Abrysvo in individuals aged 60 years and older to prevent lower respiratory tract disease caused by RSV.

Abrysvo, Pfizer's bivalent RSV prefusion F (RSVpreF) vaccine, is composed of 2 preF proteins specifically chosen to optimize protection against RSV A and B strains. With this approval, the FDA indicates all available trial data has proven Abrysvo to be safe and effective.

“A vaccine to help prevent RSV had been an elusive public health goal for more than half a century," stated Annaliesa Anderson, PhD, senior vice president and chief scientific officer of vaccine research and development at Pfizer. “Abrysvo will address a need to help protect older adults against the potentially serious consequences of RSV disease. We are extremely grateful to the clinical trial participants, study investigator teams and our dedicated Pfizer colleagues for their roles in making this vaccine available.”

In the more than 50 years of working to develop an RSV vaccine, Abrysvo is the world’s second-ever to be granted approval. Last month, GSK’s Arexvy (RSVPreF3 +AS01E) was approved to prevent lower respiratory tract disease (LRTD) caused by RSV in adults 60 years and older.

The FDA's decision to approve Abrysvo as well was based on data obtained from the pivotal Phase 3 clinical trial (NCT05035212) known as RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV disease). RENOIR is a global, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, immunogenicity, and safety of a single dose of the vaccine in adults aged 60 and older.

Approximately 37000 participants were enrolled in RENOIR, with half receiving RSVpreF 120 μg and the other half receiving placebo in a 1:1 ratio. RENOIR is an ongoing study, with efficacy data being collected during the second RSV season.

Edward E. Walsh, MD, Professor of Medicine at the University of Rochester Medical Center and principal investigator of the RENOIR trial, commented, "This past RSV season demonstrated the serious consequences and potential health risks this virus poses for older adults. Today’s FDA approval of Abrysvo recognizes significant scientific progress, and importantly helps provide older adults potential protection against RSV and an opportunity to improve community health by helping prevent the disease.”

RSV is a contagious virus that commonly causes respiratory illnesses worldwide. It primarily affects the lungs and breathing passages, often leading to severe illness or even death. In the US, RSV poses a considerable burden on older adults, with disease severity increasing with age and comorbidities such as chronic obstructive pulmonary disease, asthma, and congestive heart failure.

In most healthy individuals, RSV manifests with mild, cold-like symptoms. Most people recover within 2 weeks, often without knowing they had contracted RSV. Infants and young children, however, are also susceptible to the worst of RSV infection. Thus, Pfizer is also seeking approval to administer RSVpreF to pregnant persons, with the goal of preventing medically attended lower respiratory tract disease (MA-LRTD) and severe MA-LRTD caused by RSV in infants from birth to 6 months of age.

The maternal vaccine was recently recommended for approval by the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), and a decision is expected by August 21, 2023.

Regarding the use of RSV vaccines in older adults, the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) is scheduled to meet on June 21, 2023, to discuss recommendations. Pending the outcome of this meeting, Pfizer expects Abrysvo to be available in the third quarter of 2023, just ahead of the anticipated RSV season this fall.

In addition to this recent approval, Pfizer reported positive top-line results earlier this month from a Phase 3 study that evaluated the safety and immunogenicity of Abrysvo coadministered with seasonal inactivated influenza vaccine (SIIV) in adults aged 65 and older.

Furthermore, Pfizer announced its plans to conduct multiple clinical trials evaluating RSVpreF in healthy children aged 2-5 years, children aged 5-18 years with comorbidities, adults aged 18-60 years with comorbidities, and adults aged 18 years and older who are immunocompromised and at high risk for adverse RSV outcomes.

Contagion is actively following all developments in the RSV space. Return soon for updates, or click here to browse our past breaking news coverage and interviews with lead researchers.

Source link

Pfizer received approval from the FDA for ABRYSVO (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older. ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains and was observed to be safe and effective.
 
The decision is based on data from the Phase 3 clinical trial RENOIR, a global, randomized, double-blind, placebo-controlled study designed to assess the efficacy, immunogenicity, and safety of a single dose of the vaccine in adults 60 years of age and older. RENOIR has enrolled approximately 37,000 participants, randomized to receive RSVpreF 120 μg or placebo in a 1:1 ratio. RENOIR is ongoing, with efficacy data being collected in the second RSV season in the study.
 
Trial results published in April showed 67% efficacy in preventing infections with at least two symptoms. Protection was even greater against more severe disease, defined as three or more symptoms of RSV-related illness.
 
RSV is a contagious virus and a common cause of respiratory illness worldwide. The virus can affect the lungs and breathing passages of an infected individual, potentially causing severe illness or death. The severity of RSV disease can increase with age and comorbidities, such as chronic obstructive pulmonary disease, asthma, and congestive heart failure.
 
The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) will meet on June 21, 2023, to discuss recommendations for the appropriate use of RSV vaccines in older adults. Pending the outcome of this meeting, Pfizer anticipates supply availability in Q3 2023 ahead of the anticipated RSV season this fall.
 
Pfizer reported positive results from the Phase 3 study evaluating the safety and immunogenicity of ABRYSVO co-administered with seasonal inactivated influenza vaccine (SIIV) in adults 65 years and older. Pfizer is initiating multiple clinical trials evaluating RSVpreF in healthy children ages 2-5; children ages 5-18 with underlying medical conditions; adults ages 18-60 at high-risk due to underlying medical conditions; and adults ages 18 and older who are immunocompromised and at high-risk for RSV.

Source link

RSV, influenza, and Covid-19 outbreaks have dominated this winter.

But as the season was ending, a little-known virus called human metapneumovirus, or HMPV, which causes similar symptoms, such as lower lung infection, cough, runny nose, sore throat, and fever, was just getting started.

According to respiratory virus surveillance systems run by the US Centres for Disease Control and Prevention (CDC), cases of human metapneumovirus, or HMPV, increased this spring.

The most vulnerable populations for these infections — young children and the elderly — were overrepresented in hospital intensive care units, reported CNN.

Nearly 11 per cent of tested specimens were HMPV positive at their peak in mid-March, a figure that is roughly 36 per cent higher than the typical, pre-pandemic seasonal peak of seven per cent test positivity.

Here is all the information you need to know about the respiratory virus that this season went completely unnoticed.

Also read: COVID-19: India reports 1,272 new cases, three deaths

What is human metapneumovirus?

According to the CDC, human metapneumovirus, or HMPV, is an illness that affects the upper respiratory system.

While it can affect people of all ages, the federal agency United States Food and Drug Administration (FDA) notes that the risk is higher for small children, older adults, and those with compromised immune systems.

The CDC says HMPV was discovered by Dutch virus hunters in 2001 and is a member of the Pneumoviridae family, which also includes the respiratory syncytial virus, explained Wion News.

They collected 28 samples from kids in the Netherlands who had respiratory infections that were not explained. Even though several of the kids were critically unwell and needed mechanical ventilation, no known infections were found in their blood, reported CNN.

Although human metapneumovirus only makes up a small part of all unknown viruses, it accounts for around the same number of infections as RSV or influenza. But nobody is aware of it. Dr John Williams, a paediatrician at the University of Pittsburgh who has devoted his career to studying HMPV vaccines and treatments, refers to it as “the most important virus you’ve never heard of.”

Also read: Explained: The killer fungus wiping out the frog species

What are the symptoms?

The American Lung Association (ALA) states that people with HMPV experience mild symptoms like colds. In healthy people, symptoms typically subside on their own after two to five days.

According to the CDC, frequent symptoms include cough, fever, nasal congestion, and shortness of breath.

Young children, the elderly, and people with compromised immune systems are more likely to experience more severe illness, wheezing, breathing difficulties, and asthma flare-ups.

Secondary infections, such as bronchiolitis, bronchitis, and pneumonia, can also happen and may call for medical treatment, according to the ALA.

Also read: China’s Covid spike: What we know about the new omicron variant BF.7

How is it transmitted?

According to the CDC, human metapneumovirus has been spreading similarly to other viruses through airborne particles produced by coughing and sneezing, physical contact with an infected person, or handling objects contaminated with the virus before touching the nose, eyes, or mouth.

Like the flu, RSV, and cold viruses, the CDC believes the virus is more likely to spread throughout the winter and spring months.

Also read: Did the world’s first human fatality from H3N8 bird flu catch the virus at a wet market in China?

Is there a vaccine for the virus?

As per CDC, there is no vaccine to protect against HMPV or antibiotic medication to treat it.

Wion quoted William Schaffner, a professor of infectious diseases and preventive medicine at Vanderbilt University, as saying, “We try to make you feel better and make sure that your breathing is okay while your body fights off the virus.”

He believes serious situations in which persons have been reported to be having respiratory problems are uncommon, adding that although “We can put them in an intensive care unit and treat them there,” most people recover fully on their own.

Human metapneumovirus is a respiratory virus that has been around for decades, as opposed to the novel coronavirus and its subtypes that cause covid, Monica Gandhi, an infectious-disease expert at the University of California in San Francisco said, according to Wion.

“Hopefully, in the future, we will actually see advances against human metapneumovirus. But we’ve been living with it for a long time. This is not one that is going to cause a pandemic,” she stated.

The American Lung Association states that over-the-counter drugs are often used as a treatment for HMPV symptoms because they typically go away on their own. The voluntary health organisation advises patients with more severe symptoms, such as wheezing, to seek medical attention. A doctor may then prescribe steroids and a temporary inhaler.

Viral infections are not treated with antibiotics; only bacterial infections are. But USA Today quoted Dr Rick Malley, an infectious disease specialist at Boston Children’s Hospital, as saying that HMPV is linked to a higher chance of getting bacterial pneumonia, which is normally treated with medicines.

“This virus is probably a very important co-conspirator in causing pneumonia, specifically pneumococcal pneumonia,” he claimed. “Just because a person has a virus doesn’t necessarily mean that there isn’t a bacterium nearby.”

How to prevent yourself from the virus?

It is possible to lessen the risk of hMPV transmission by maintaining excellent hygiene, which includes routine hand washing, concealing coughs and sneezes, and avoiding close contact with sick people.

Following general preventative measures against respiratory illnesses, such as receiving a flu shot and having a strong immune system, can also offer additional security.

With inputs from agencies

Read all the Latest NewsTrending NewsCricket NewsBollywood News,
India News and Entertainment News here. Follow us on FacebookTwitter and Instagram.

 



Source link

Influenza Medication Market - Revolutionizing Flu Treatment:

Newark, New Castle, USA - new report, titled Influenza Medication Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Influenza Medication market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Influenza Medication market. The report offers an overview of the market, which briefly describes the market condition and the leading segments. It also mentions the top players present in the global Influenza Medication market.

Influenza Medication Market: www.growthplusreports.com/report/influenza-medication-market/7859

Global Influenza Medication Market: Segmentation

For a point by point assessment, the global Influenza Medication market is divided basis of technology, product, and services. This division of the market permits a detailed scrutiny of the large number of components affecting the market. Analysts have fastidiously examined the changing example of innovation, upcoming trends, ventures made by players in innovative work, and growing number of applications. Moreover, experts have evaluated the changing socioeconomics and changing utilization designs, which are impact the global Influenza Medication market.

Get a PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, and Chart) : www.growthplusreports.com/inquiry/request-sample/influenza-medication-market/7859

SEGMENTATION

GLOBAL INFLUENZA MEDICATION MARKET - ANALYSIS & FORECAST, BY TREATMENT TYPE
Oseltamivir Phosphate
Baloxavir Marboxil
Others (Zanamivir)

GLOBAL INFLUENZA MEDICATION MARKET - ANALYSIS & FORECAST, BY INFLUENZA TYPE
Influenza Type A
Influenza Type B

GLOBAL INFLUENZA MEDICATION MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Influenza Medication Market Competitive Landscape

The last chapter of the research report on the global Influenza Medication market focuses on the key players and the competitive landscape present in the market. The report includes a list of strategic initiatives taken by the companies in recent years along with the ones that are expected to happen in the foreseeable future. Researchers have made a note of the financial outlook of these companies, their research and development activities, and their expansion plans for the near future. The research report on the global Influenza Medication market is a sincere attempt at giving the readers a comprehensive view of the market to interested readers.

Influenza Medication Market Leading Players:

Sanofi S.A
Lupin Limited
Teva Pharmaceutical Industries Ltd.
Shionogi & Co. Ltd
Macleods Pharmaceutical Ltd.
Alvogen Pvt.Ltd
AstraZaneca Plc.
BioCryst Pharmaceuticals Inc.
F. Hoffman La Roche Ltd.
Novartis AG
Vitaris AG

Growth Plus Reports studies the key trends in each category and sub-segment of the Influenza Medication market, along with global and regional projections from 2022 to 2030. Our research splits the market into product type and application segments.

For More Information or Query or Customization visit: www.growthplusreports.com/inquiry/customization/influenza-medication-market/7859

This report is useful in addressing various essential issues for market participants, while also supporting them in making investments and leveraging the market opportunities.

Influenza Medication Market TOC: www.growthplusreports.com/report/toc/influenza-medication-market/7859

Market segment by Region/Country including: -

-North America (United States, Canada and Mexico)
-Europe (Germany, UK, France, Italy, Russia and Spain etc.)
-Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)
-South America (Brazil, Argentina and Colombia etc.)
-Middle East and Africa (South Africa, UAE and Saudi Arabia etc.)

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Influenza Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Influenza Medication industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza Medication .

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

QUICK BUY: www.growthplusreports.com/checkout-7859

Browse Latest Healthcare Reports:

Human Metapneumovirus Treatment Market: www.growthplusreports.com/report/human-metapneumovirus-treatment-market/8676

Genital Warts Market: www.growthplusreports.com/report/genital-warts-market/8677

Medical Assistive Robots Market: www.growthplusreports.com/report/medical-assistive-robots-market/8678

Human Chorionic Gonadotropin Market: www.growthplusreports.com/report/human-chorionic-gonadotropin-market/8679

Neuronal Ceroid Lipofuscinoses Cln1 Market: www.growthplusreports.com/report/neuronal-ceroid-lipofuscinoses-cln1-market/8680

Urinary Stents Market: www.growthplusreports.com/report/urinary-stents-market/8681

Rotavirus Vaccines Market: www.growthplusreports.com/report/rotavirus-vaccines-market/8682

Biohazard Bags Market: www.growthplusreports.com/report/biohazard-bags-market/8683

AL Amyloidosis Therapeutics Market: www.growthplusreports.com/report/al-amyloidosis-therapeutics-market/8684

Manan Sethi
Director, Market Insights
Email: [email protected]
Phone no: +1 888 550 5009
Web: www.growthplusreports.com/

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020."

This release was published on openPR.

Source link

used facial tissue

What Is Human Metapneumovirus, Exactly?PhotoAlto/Michele Constantini - Getty Images

  • Cases of human metapneumovirus (HMPV) rose sharply this spring, according to the CDC.

  • HMPV was first discovered in 2001.

  • There’s a lot experts are still learning about HMPV.

There are some viruses most people are at least aware of, like RSV and the flu. But then there are some that are common but most people have never heard of before. Human metapneumovirus (HMPV) falls into the latter camp.

According to the Centers for Disease Control and Prevention (CDC), cases of HMPV skyrocketed this spring. CDC data show that in mid-March, nearly 11% of tested specimens came back positive for HMPV.

“We’re seeing spikes in all sorts of communicable infectious diseases lately,” says Thomas Russo, M.D., an infectious disease expert at the University of Buffalo in New York. “People have gone back to their lives and are interacting again. If someone has an infectious disease like human metapneumovirus, it will spread.”

Never heard of HMPV before? You’re not alone. While experts say most people who get it aren’t even aware that they have it, this is a virus that has the potential to make you seriously ill. Here’s the deal with human metapneumovirus, plus symptoms to look out for.

What is human metapneumovirus (HMPV)?

Human metapneumovirus is a virus that can cause upper and lower respiratory tract infections, according to the CDC. While anyone can get it, it’s a larger concern in young children, older adults, and people with weak immune systems, Dr. Russo says.

HMPV is kind of a newly-discovered virus—it was first detected in 2001. It’s also in the Pneumoviridae family along with respiratory syncytial virus (RSV), the CDC says. The virus circulates in winter and lasts until or through spring.

“It’s another one of the gang of respiratory viruses that cause the common cold and, occasionally, a more serious pneumonia-like illness,” says William Schaffner, M.D., an infectious disease specialist and professor of medicine at the Vanderbilt University School of Medicine. “It’s been out there all along, but we’re now getting better at testing for it and naming it.”

What are the signs and symptoms of HMPV?

The CDC says the following are the most common symptoms of HMPV:

  • Cough

  • Fever

  • Nasal congestion

  • Shortness of breath

Those symptoms are similar to a lot of other illnesses, including the flu—and even doctors can’t tell the difference by examining you. “It’s not possible to distinguish HMPV clinically from influenza,” says infectious disease expert Amesh A. Adalja, M.D., a senior scholar at the Johns Hopkins Center for Health Security. “HMPV is a cause of ‘the cold’—which is a syndrome that caused by many different viruses.”

How does HMPV spread?

The virus is believed to spread from person to person the same way as many other viruses, per the CDC. That includes:

  • Secretions from coughing and sneezing

  • Close personal contact, like touching or shaking hands

  • Touching objects or surfaces that have the viruses on them then touching the mouth, nose, or eyes

Ultimately, though, “we’re still learning about this,” Dr. Russo says.

HMPV prevention

The CDC recommends doing the following to lower your risk of getting HMPV:

  • Wash your hands often with soap and water for at least 20 seconds.

  • Avoid touching your eyes, nose, or mouth with unwashed hands.

  • Avoid close contact with people who are sick.

But Dr. Russo says that HMPV is “much less” infectious than COVID-19, the flu, and RSV.

HMPV treatment

There is no specific antiviral treatment for HMPV. “It’s not even something we usually look for,” Dr. Russo says. But Dr. Adalja points out that respiratory viral panels (i.e. tests) have made it “much easier” to diagnose HMPV, which is included in the diagnostic workup.

If you have HMPV-like symptoms, Dr. Schaffner recommends that you get tested to rule out the flu and COVID-19. If your doctor suspects that you have HMPV, they’ll likely just recommend supportive treatments, like a decongestant to help relieve stuffiness and acetaminophen or ibuprofen for your fever.

HMPV doesn’t commonly cause serious complications like pneumonia, but it can. “For most people, this is one of those viruses that comes and goes—you never even know you had it,” Dr. Russo says.

You Might Also Like

Originally published

Source link

An important aetiologic agent of upper respiratory tract infection (URTI) and lower respiratory tract infection (LRTI) in adults and children is the human metapneumovirus (HMPV). A recent Journal of Infection study explores the genetic diversity, prevalence, and evolutionary dynamics of HMPV.

Study: The emergence, impact, and evolution of human metapneumovirus variants from 2014 to 2021 in Spain. Image Credit: VO IMAGES / Shutterstock.com Study: The emergence, impact, and evolution of human metapneumovirus variants from 2014 to 2021 in Spain. Image Credit: VO IMAGES / Shutterstock.com

Background

HMPV belongs to the Pneumoviridae family and causes similar symptomatology as the human respiratory syncytial virus (HRSV). HMPV is a negative-sensed, lineal, enveloped, and single-stranded ribonucleic acid (RNA) virus that can be classified into HMPV-A and HMPV-B genotypes, with its subgenotypes including A1, A2 (A2a, A2b, and A2c lineages), B1, and B2 (B2a and B2b lineages).

The genome of HMPV consists of eight genes encoding nine proteins. The scheme in which the proteins are encoded is 3’-N-P-M-F-M2(M2–1/M2–2)- SH-G-L-5’.

Recently, in the attachment glycoprotein’s (G) ectodomain,  180- and 111-nucleotide duplications have been associated with LRTI and immune evasion in adulthood. 

About the study

The current study aimed to characterize the evolutionary dynamics and genetic diversity of HMPV in adult and pediatric patients at a university hospital in Barcelona in the seasons between 2014-2015 and 2020-2021.

Laboratory-confirmed HMPV was characterized based on partial-coding G gene sequences. For the assembly of nucleotide sequences, the MEGA.v6.0 was used.

Phylogenetic trees were constructed based on the lowest Bayesian information criterion score. These trees were evaluated with 1,000 bootstrap resamplings. Whole genome sequencing (WGS) was performed with Illumina, and evolutionary analyses with Nextstrain and Datamonkey.

Key findings

Consistent with other studies, the prevalence of HMPV in pre-pandemic years was similar, with an annual seasonal pattern and clear peak. However, the start of the coronavirus disease 2019 (COVID-19) pandemic disrupted the circulation of HMPV. From the summer of 2020, enveloped viruses were circulating; however, HRSV or HMPV were not dominant.

In the summer of 2021, HMPV and HRSV were again in circulation and caused two epidemic peaks, the second of which started in the autumn. This could be due to a lack of viral interference at that time or the relaxation of preventive measures by Spanish people. During the second peak, the prevalence of HMPV was higher compared to previous seasons, likely because two generations had not yet experienced primary infection.

The most common co-detections were adenovirus, rhinovirus, bocavirus, and enterovirus. The co-detection rate increased after the COVID-19 pandemic, and a change was observed in most common co-detected viruses.

HMPV had shown a higher incidence among children under two years of age in pre-pandemic seasons; however, this changed during the pandemic. There was also a higher tendency of male infants to be affected. In contrast, in the adult population, females and individuals 50 years of age or older were more likely to be infected.

A pattern of cyclic shifts of predominance with respect to the circulation of HMPV-A was observed. In addition, an increasing prevalence of A2c viruses carrying duplications was observed, with A2c180dup first described, followed by A2c111dup. The dominance of A2c111dup indicates that the 180-nucleotide duplication covers much of the F protein, which could impact membrane fusion and prevent virus replication.

Consistent with the rise in prevalence of A2c variants and their dominance during the COVID-19 pandemic, an increase in the morbidity of HMPV infections had also been described at the end of the 2009 influenza A(H1N1)pdm09 pandemic. At this time, A2c exhibited a higher mean genetic distance and immune evasive characteristics that contributed to its aggressive predominance.

Conclusions

HMPV affected both pediatric and adult populations and showed significant morbidity throughout the study period. The HMPV epidemic was disrupted by the COVID-19 pandemic in 2020, which led to two unexpected peaks later in the summer and autumn of 2021.

WGS showed the high conservation of the F protein and rich diversity in G protein, thus indicating the necessity for steric shielding of G over F. The current study is an effective example of virological surveillance of a non-HRSV or influenza respiratory virus. It provides crucial information on the real-time evolution of HMPV and its impact on public health.

Journal reference:

  • Pinana, M., Gonzalez-Sanchez, A., Andres, C., et al. (2023) The emergence, impact, and evolution of human metapneumovirus variants from 2014 to 2021 in Spain. Journal of Infection. doi:10.1016/j.jinf.2023.05.004

Source link

The Centers for Disease Control and Prevention (CDC) has recently reported that Human Metapneumovirus (HMPV) has filled intensive care units with children and seniors this spring. HMPV is a viral respiratory illness that is closely related to Respiratory Syncytial Virus (RSV). It is capable of causing severe respiratory illness in people, similar to influenza.

CNN has reported that HMPV is the second most common illness in children, behind RSV. Just like RSV and the flu, HMPV can cause people to be admitted to intensive care units, and in the case of older patients, it can lead to deadly cases of pneumonia.

The virus was first identified in 2001 by Dutch virus hunters who analysed 28 samples collected from children in the Netherlands with unexplained respiratory infections. These children had not tested positive for any known illnesses but all had been seriously ill and needed to be placed on ventilators.

A study published in Lancet Global Health in 2020 found that more than 14 million cases of HMPV infections were recorded in children under 5 years old, with over 600,000 hospitalizations and over 16,000 deaths.

The CDC has stated that the symptoms commonly associated with HMPV include cough, fever, nasal congestion, and shortness of breath. These symptoms may progress to bronchitis or pneumonia, similar to other viruses that cause upper and lower respiratory infections.

According to reports, the average incubation period for HMPV is around three to six days, and the median duration of illness can vary depending upon severity but is similar to other respiratory infections caused by viruses. Additionally, the CDC states that HMPV circulates in distinct annual seasons, beginning in the winter and lasting throughout spring.

It is essential to note that HMPV, RSV, and influenza can spread simultaneously. Therefore, individuals who develop any of the symptoms associated with HMPV, RSV, and/or influenza should seek immediate medical attention to prevent potential complications.

As of this moment, the CDC has not approved of the COVID-19 vaccine for children younger than 12 years.

Credit: wftv.com

ENND

Source link

The United States is currently witnessing the emergence of a novel virus called Human Metapneumovirus (HMPV), which is increasingly being recognized as a significant contributor to acute respiratory infections.

Also read | Nascar accused of favoring Denny Hamlin after Chase Elliott’s suspension

HMPV is a respiratory virus that can cause various illnesses ranging from mild to severe in people of all ages. While it is most commonly found in children, the virus can also affect older adults and people with compromised immune systems.

HMPV virus symptoms

The symptoms of the HMPV virus are identical to other respiratory illnesses, such as the common cold, cough, fever, fatigue, muscle aches, shortness of breath, and pneumonia. The symptoms may differ from patient to patient depending upon the severity.

Also read | Who is Melanie Hamrick, Mick Jagger’s girlfriend? 

Test

Doctors can diagnose HMPV. They can ask for samples from the nose and throat. Rapid antigen tests or PCR test samples can also be used, and for severe cases, a bronchoscopy.

Cause

HMPV is primarily transmitted through close contact with infected people, as well as coughing, sneezing, and contact with virus-contaminated surfaces. It circulates more during the winter and spring seasons, coinciding with the activity of other common viruses like influenza and cold viruses.

Also read | Who is Jim Lucas? Indiana rep arrested after crashing his vehicle on Interstate 65

HMPV typically has an incubation period of 3-7 days. If a person has been exposed to the virus, symptoms will appear and become noticeable in 3-7 days.

Cure

There is currently no targeted antiviral therapy or vaccine available for HMPV. In most cases, the infection resolves on its own, and treatment focuses primarily on symptom management. Pain relievers, fever reducers, and congestion relievers are available over-the-counter. For severe cases, medical attention is required.

Also read | Who is Christina Sandera, Clint Eastwood’s girlfriend?

Prevention

Adopting good hygiene practices, such as handwashing on a regular basis, covering coughs and sneezes, and avoiding close contact with sick people, can significantly reduce the risk of HMPV transmission.

Source link

In Part 1 of this series, I noted that mRNA vaccines were hustled into commercial viability by Operation Warp Speed, a federal program set up in 2020 to accelerate the development of any vaccine that might stave off COVID-19's most severe symptoms.

The sudden appearance of a brand new kind of vaccine has generated concerns ranging from the spurious to the undeniable. Like all vaccines, the ones for COVID-19 can cause side effects -- a problem that may have a lot to do with how mRNA currently gets delivered -- and, as readers of Part 2 of the series have learned, Stanford Medicine researchers are bent on minimizing them. While Part 1 explained how the new vaccines work and how they're packaged for delivery to our immune systems, Part 2 focused on potential improvements in mRNA vaccine delivery that could both minimize side effects and get more bang for the dose.

To sum it up, lipid nanoparticles -- the mRNA delivery vehicles in commercial use today -- don't always deliver their mRNA cargo to their target cells, and sometimes deliver it to the wrong places. And only about one-tenth of the mRNA that reaches a targeted cell is actually converted into the protein meant to trigger an immune response. Potentially superior delivery technologies, which I described in detail in Part 2, may address those shortcomings.

The biggest source of mRNA vaccine skepticism, according to vaccinologist Bali Pulendran, PhD, the Violetta L. Horton Professor and professor of pathology and of microbiology and immunology, is rooted not in biology but in our own psychology -- specifically, an amorphous, free-floating fear of the unknown.

"The human mind rejects any new idea like the body rejects a transplanted organ," he said.

Everything, everywhere, all at once

COVID-19 was the launchpad for mRNA vaccine technology. As the world emerges from the worst of the pandemic, can the same platform dispatch mRNA vaccines aimed at pretty much any microbe of choice? 

Pulendran answers with a resounding yes.

"Any vaccine you can think of, the mRNA companies are working on it," said Pulendran, who has consulted with Moderna, Pfizer and BioNTech, three companies closely associated with the new technology. "Their world view is that mRNA technology will replace all preceding ones. The future is extremely bright for mRNA vaccines."

Pulendran noted a couple of criticisms that have been leveled at the mRNA-based COVID-19 vaccines. "They've been very good at preventing severe disease, hospitalization and death," he said. "So far, they haven't been so good at preventing infection for long periods of time -- particularly in the face of ever-newer viral variants - and they haven't been great at preventing transmission."

But transmission, or the spreading of a virus from person to person, is a problem common to all respiratory infections, he said. It's tough to completely prevent infection of the nose and throat with any vaccine, considering these outward-facing cavities' cells are constantly exposed to the air -- and, consequently, the microbes -- we inhale.

"To me, the most critical goal of a vaccine is to prevent severe or even moderate disease," Pulendran said. "A mild COVID 'cold' may even benefit us by keeping our immune system on its toes." On the other hand, he said, mRNA vaccines employing delivery systems that target the mucus-secreting linings of our airways and gut may prove more effective at durably preventing infection.

Was the technology that rescued people most susceptible to depredations of SARS-CoV-2 -- the virus that causes COVID-19 -- a one-hit wonder, or was it a cornucopia conferring protection from microbial menaces of every stripe? Time will tell.

And it won't take long. Clinical testing is underway for mRNA-based vaccines for influenza, HIV, cytomegalovirus (a ubiquitous microbe that usually causes no symptoms but can harm immunocompromised people), dengue, rabies and several other viruses, as well as for malaria, tuberculosis and other non-viral microbes. Moderna is submitting its mRNA-based vaccine directed at respiratory syncytial virus to the FDA for approval. Moderna and Merck are collaborating on a personalized skin-cancer vaccine employing mRNA, now in clinical trials.

These are all familiar, if uninvited, maladies. What humanity should most fear -- and what the plug-and-play mRNA vaccine technology promises to provide the most valiant and rapid defense against -- are those next unfamiliar monsters climbing over the hill toward us, which science-fiction movies always seem to depict as giants but are actually microscopic.

Read the other stories in this series:  

Part I: Special delivery - an mRNA explainer

Part II: Special delivery 2.0: CARTs

Photo by xyz+

Source link

(CNN) - A little-known respiratory virus causes symptoms like the flu and COVID-19, and spiked this spring, according to numbers from the U.S. Centers for Disease Control and Prevention.

It’s also led to hospitalizations among many of the most vulnerable, like young children and seniors.

It’s called human metapneumovirus or HMPV, a virus that wreaked havoc on the U.S. this spring, filling some hospitals with young children and seniors, according to the CDC.

“The symptoms are identical almost to influenza and respiratory syncytial virus,” said Dr. Jorge Rodriguez, a board-certified internal medicine specialist.

Those symptoms include a hacking cough, runny nose, fever and shortness of breath.

At its peak in mid-March, nearly 11% of tested specimens were positive for HMPV.

“What is most concerning is the fact that it has increased approximately 36% in the last year,” Rodriguez said.

The virus has been around for a while. Health experts believe pandemic precautions, like masking, kept it at bay.

“Now that we’ve let down our defenses, now that we are not as cautious, all these viruses - think of it this way -- were just waiting to pounce, and indeed, they are pouncing,” Rodriguez said.

Most people who caught HMPV probably didn’t even know they had it.

Sick people aren’t usually tested for it outside of a hospital or emergency room.

Unlike COVID-19 and the flu, there’s no vaccine for HMPV or antiviral drugs to treat it. Instead, doctors care for seriously sick patients by tending to their symptoms.

“The best treatment is precaution and prevention,” Rodriguez said.

Health experts said that’s why it’s important to be aware of this virus, especially if those most vulnerable to it get sick.

“Monitor them,” Rodriguez said. “If they get sicker, for example, if they get short of breath or their fever spikes up above 103 or 104 (degrees Fahrenheit), then you need to go see a physician.”

Because testing for HMPV is rarely done outside hospitals, it’s hard to know the true burden of the disease.

Blood tests indicate that most children have had it by the age of 5.

A 2021 study in the Lancet Global Health estimated that among children younger than 5, there were more than 14 million HMPV infections around the world in 2018, more than 600,000 hospitalizations and more than 16,000 deaths.

Source link

Just as the world started to recover from COVID-19, a new virus called human metapneumovirus (HMPV) is emerging. HMPV is a respiratory virus that can cause symptoms similar to other respiratory illnesses, such as the common cold, RSV, and pneumonia. Read below to learn more

What is Human Metapneumovirus?

The Centers for Disease Control and Prevention (CDC) states “Discovered in 2001, HMPV is in the Pneumoviridae family along with respiratory syncytial virus (RSV). Broader use of molecular diagnostic testing has increased identification and awareness of HMPV as an important cause of upper and lower respiratory infection.”

Human metapneumovirus (HMPV) is a respiratory virus that causes mild to severe illness in people of all ages. Although it is common with young children, the virus also affects older adults and people that have weak immune systems. 

The CDC has mentioned that there has been a surge in the cases of HMPV and the reason is unknown. The percentage of positive cases for HMPV surged to a high of 19.6% for Antigen tests and 10.9% for PCR tests. 

Jagranjosh Source: Centers for Disease Control and Prevention

CDC also mentioned that in the US, the outbreak of HMPV usually occurs during late fall, spring, and winter and it declines during the summer just like any normal flu or cold infection. 

What are the Causes of Human Metapneumovirus? 

HMPV can be spread through respiratory droplets that are produced when an infected person coughs or sneezes. Here are the causes of the spread of Human Metapneumovirus: 

  • Respiratory droplets: HMPV is spread through respiratory droplets that are produced when an infected person coughs or sneezes. These droplets can reach the mouth of people nearby. 
  • Contact with contaminated surfaces: HMPV can also be spread by touching a surface or object that has the virus on it and then touching your eyes, nose, or mouth.

The incubation period for HMPV is 3-7 days. This means that it will take 3-7 days to show symptoms if a person has been exposed to the virus.

There are certain cases where the HMPV infection can lead to major issues such as pneumonia or bronchitis. The CDC states “Clinical symptoms of HMPV infection may progress to bronchitis or pneumonia and are similar to other viruses that cause upper and lower respiratory infections.” 

What are the Symptoms of Human Metapneumovirus? 

The symptoms of this infection can vary from person to person depending on their age, and overall health. However, here are the common symptoms of HMPV:

Upper respiratory issues: HMPV usually shows symptoms just like a common cold that include a runny or stuffy nose, sore throat, and cough. 

Cough: The cough can be persistent and may worsen over time.

Fever: Many individuals infected with HMPV develop a fever, although not everyone experiences this symptom. 

Shortness of breath: The virus can cause breathing difficulty, especially in infants, young children, and older adults. 

Fatigue: Feeling tired or experiencing a lack of energy is common during any respiratory infection, including HMPV.

Muscle aches: Some individuals infected with HMPV may experience muscle aches or body pains.

It is essential to know that these symptoms can resemble those of other respiratory viruses such as Respiratory Syncytial Virus (RSV).

The National Library of Medicine mentioned that “Adult patients with an HMPV infection might be asymptomatic or might have symptoms ranging from mild upper RTI symptoms to severe pneumonia. 

“Most patients present with cough, nasal congestion and dyspnoea. Purulent cough, wheezing, sore throat, fever, pneumonia, bronchi(oli)tis, conjunctivitis and otitis media are other reported symptoms. Described a HMPV infection in an immunocompetent adult presenting as a mononucleosis-like illness. 

“Adults with HMPV infection were less likely to report fever in contrast to adults with RSV or influenza infection. In addition, adults with an HMPV infection presented more often with wheezing compared to adults with RSV or influenza. Falsey et al. showed that this is mainly in the elderly population (>65 years). 

“Elder patients also showed more dyspnoea compared to younger adults. Young adults with HMPV infection had greater complaints of hoarseness. In the frail elderly patients, the patients with pulmonary or cardiovascular disease and immunocompromised patients, infections can be severe.” 

To conclude, Human Metapneumovirus is a common respiratory virus that can cause a range of symptoms that might go away on its own. To ensure safety from this virus, CDC recommends following basic hygiene tips such as washing hands frequently and maintaining appropriate distance from people who are sick. 

Source link